*僅供醫學專業人士閱讀參考

前沿數據解讀，分析新型生物制劑療效和安全性。

*以下內容僅供在中國大陸執業的

醫療衛生專業人士瀏覽。

參考文獻：

[1].Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36.

[2].Xin H, Harris LA, Aban IB, Cutter G. Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. J Clin Neurol. 2019 Jul;15(3):376-385.

[3].Utsugisawa K Nagane Y Uzawa A Murai H Imai T Suzuki S. Health-related quality of life and treatment strategies in myasthenia gravis. Clin Exp Neuroimmunol. 2020; 11: 209-217

[4].Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018 Oct;10(7):1111-1130.

[5].Brennan FR, Morton LD, Spindeldreher S, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010 May-Jun;2(3):233-55.

[6].Angal S, King DJ, Bodmer MW, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993 Jan;30(1):105-8.

[7].Bril V, Dru?d? A, Grosskreutz J; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394.

[CN-RZ-2500015 有效期截止：2027年4月] 本文章僅供醫療衛生專業人士閱讀，所含信息不應代替醫療衛生專業人士提供的醫療建議，也不建議醫療衛生專業人士超出說明書范圍使用所涉及的藥物。